Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends

The antibody–drug conjugate (ADC) field is in a transitional period. Older approaches to conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but preclinical work is driving a rapid evolution in how we strategize to improve efficacy and reduce toxicity towards better t...

Descripción completa

Detalles Bibliográficos
Autores principales: Drake, Penelope M., Rabuka, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696438/
https://www.ncbi.nlm.nih.gov/pubmed/29119409
http://dx.doi.org/10.1007/s40259-017-0254-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696438/
https://www.ncbi.nlm.nih.gov/pubmed/29119409
http://dx.doi.org/10.1007/s40259-017-0254-1

Ejemplares similares